Compare
Bicara Therapeutics Inc. vs Arcutis Biotherapeutics, Inc. vs BGM Group Ltd. vs MoonLake Immunotherapeutics
| Latest fiscal year | Bicara Therapeutics Inc. BCAX | Arcutis Biotherapeutics, Inc. ARQT | BGM Group Ltd. BGM | MoonLake Immunotherapeutics MLTX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-09-30 | 2025-12-31 |
| Revenue | n/a | $372.07M | $37.92M | n/a |
| Revenue growth (YoY) | n/a | +123.4% | +51.1% | n/a |
| Gross margin | n/a | 90.1% (computed) | 16.6% | n/a |
| Operating margin | n/a | -3.3% | -33.2% | n/a |
| Net margin | n/a | -4.3% | -52.6% | n/a |
| Net income | -$137.95M | -$16.14M | -$19.94M | -$227.32M |
| EPS (Diluted) | -$2.52 | -$0.13 | -$0.18 | -$3.53 |
| Operating cash flow | -$106.83M | -$5.62M | -$2.37M | -$196.01M |
| Free cash flow | -$107.11M | -$6.31M | -$3.94M | -$196.04M |
| Cash & equivalents | $96.69M | $42.91M | $9.82M | $334.52M |
| Total assets | $430.99M | $432.97M | $433.81M | $424.43M |
| Total liabilities | $29.54M | $243.49M | $41.92M | $119.95M |
| Shareholders' equity | $401.45M | $189.48M | $391.90M | $304.48M |
| Return on year-end equity | -34.4% | -8.5% | -5.1% | -74.7% |
| Shares outstanding | 56.60M | 123.33M | 200.62M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Bicara Therapeutics Inc. | Arcutis Biotherapeutics, Inc. | BGM Group Ltd. | MoonLake Immunotherapeutics |
|---|---|---|---|---|
| Latest | n/a | $372.07M Ended 2025-12-31 | $37.92M Ended 2025-09-30 | n/a |
| 1 year earlier | n/a | $166.54M Ended 2024-12-31 | $25.10M Ended 2024-09-30 | n/a |
| 2 years earlier | n/a | $59.61M Ended 2023-12-31 | $46.47M Ended 2023-09-30 | n/a |
| 3 years earlier | n/a | $3.69M Ended 2022-12-31 | $64.86M Ended 2022-09-30 | n/a |
| 4 years earlier | n/a | $0 Ended 2021-12-31 | $57.10M Ended 2021-09-30 | n/a |